GSK's cell therapy retreat hits another partner as drugmaker exits Immatics collaboration

It turns out that GSK’s broad retreat from cell therapies went even deeper than it let on.

As Immatics, which scored $50 million upfront from GSK back in 2020 to collaborate on two T cell receptor therapies for solid tumors, revealed in its Q3 update:

On October 24, 2022, GSK provided Immatics with notice of its decision to terminate their collaboration.